Tyler Wilhite, MD

1. Jethwa KR, Hellekson CD, Evans JD, Harmsen WS, Wilhite TJ, Whitaker TJ, Park SS, Choo CR, Stish BJ, Olivier KR, Haloi R, Lowe VJ, Welch BT, Quevedo F, Mynderse LA, Karnes RJ, Kwon ED, Davis BJ. 11C-choline PET-guided salvage radiotherapy for isolated pelvic and para-aortic nodal recurrence of prostate cancer after radical prostatectomy: rationale and early genitourinary or gastrointestinal toxicities. Adv Radiat Oncol. 2019; Accepted June 21.

2. Garant A, Whitaker TJ, Spears GM, Routman DM, Harmsen WS, Wilhite TJ, Ashman JB, Sio TT, Rule WG, Neben Wittich MA, Martenson JA, Tryggestad EJ, Yoon HH, Blackmon S, Merrell KW, Haddock MG, Hallemeier CL. A comparison of patient-reported health-related quality of life during proton versus photon chemoradiotherapy for esophageal cancer. Pract Radiat Oncol. 2019; Accepted July 2.

3. Wilhite TJ, Youland RS, Tian S, Finley R, Sarkaria JN, Corbin KS. Pathogenic germline variants in a patient with severe toxicity from breast radiotherapy. Clinical Breast Cancer. 2019 Mar 28;S1526-8209(18):30860-7.

4. Wilhite TJ, Routman D, Arnett AL, Glasgow AE, Habermann EB, Pisansky TM, Boorjian SA, Jethwa KR, Mynderse LA,  Roberts KW, Frank I, Choo R, Davis BJ, Stish BJ. Increased external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. Bladder. 2018;5(3):e34.2.

5. Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA, Hodi FS, Schoenfeld JD. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):

344-351.

6. Chandra RA, Wilhite TJ*, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015 May 28;4(11):e1046028. *Equal contributors

7. Aizer AA, Wilhite TJ*, Chen MH, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Trinh QD, Hu JC, Nguyen PL. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014 May 15;120(10):1532-9. *Equal contributors

8. Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Hu JC, Nguyen PL. Marital status and survival in patients with cancer. J Clin Oncol. 2013 Nov 1;31(31):3869-76.

9. Wilhite T, Ezzelarab C, Hara H, Long C, Ayares D, Cooper DK, Ezzelarab M. The effect of Gal expression on pig cells on the human T-cell xenoresponse. Xenotransplantation. 2012 Jan-Feb;19(1):56-63.

10. Ezzelarab M, Ezzelarab C, Wilhite T, Kumar G, Hara H, Ayares D, Cooper DK. Genetically-modified pig mesenchymal stromal cells: xenoantigenicity and effect on human T-cell xenoresponses. Xenotransplantation. 2011 May-Jun;18(3):183-95.